You just read:

SELLAS' Galinpepimut-S Induces Specific, Robust and Durable Immune Responses in Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit

News provided by

SELLAS Life Sciences Group

Sep 14, 2017, 07:55 ET